Molecular-targeted Therapy and Surgery May Prolong Survival of Renal Cell Carcinoma Patients with Bone Metastasis: A Multi-institutional Retrospective Study in Japan

被引：12

作者：

Kitamura, Hiroshi ^{[1
]}

Takahashi, Atsushi ^{[2
]}

Takei, Fumiyasu ^{[3
]}

Hotta, Hiroshi ^{[4
]}

Miyao, Noriomi ^{[5
]}

Shindo, Tetsuya ^{[6
]}

Igarashi, Manabu ^{[7
]}

Tachiki, Hitoshi ^{[8
]}

Kunishima, Yasuharu ^{[9
]}

Muranaka, Takashi ^{[10
]}

Shigyo, Masanori ^{[11
]}

Ikehata, Yoshinori ^{[12
]}

Masumori, Naoya ^{[13
]}

机构：

[1] Toyama Univ, Toyama, Japan

[2] Hakodate Goryoukaku Hosp, Hakodate, Hokkaido, Japan

[3] Sunagawa City Med Ctr, Sunagawa, Japan

[4] Japanese Red Cross Asahikawa Hosp, Asahikawa, Hokkaido, Japan

[5] Muroran City Gen Hosp, Muroran, Hokkaido, Japan

[6] NTT East Japan Sapporo Hosp, Sapporo, Hokkaido, Japan

[7] Takikawa Municipal Hosp, Takikawa, Hokkaido, Japan

[8] Steel Mem Muroran Hosp, Muroran, Hokkaido, Japan

[9] Obihiro Kyokai Hosp, Obihiro, Hokkaido, Japan

[10] JCHO Hokkaido Hosp, Sapporo, Hokkaido, Japan

[11] Kushiro Red Cross Hosp, Kushiro, Hokkaido, Japan

[12] Oji Gen Hosp, Tomakomai, Japan

[13] Sapporo Med Univ, Sch Med, Sapporo, Hokkaido, Japan

来源：

ANTICANCER RESEARCH | 2016年 / 36卷 / 10期

关键词：

Kidney neoplasms; neoplasm metastasis; bone; molecular-targeted therapy; surgery; POPULATION-BASED ANALYSIS; PHASE-III TRIAL; CYTOREDUCTIVE NEPHRECTOMY; PROGNOSTIC-FACTORS; INTERFERON-ALPHA; SUNITINIB; ERA; BISPHOSPHONATES; EVEROLIMUS; CANCER;

D O I：

10.21873/anticanres.11136

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: To determine prognostic factors for overall survival (OS) in renal cell carcinoma (RCC) patients with bone metastasis in the targeted-therapy era. Patients and Methods: We conducted a retrospective multi-institutional review of the medical records of 149 RCC patients with bone metastasis. Survival was estimated using the Kaplan-Meier method and compared with the log-rank test. Univariate and multivariate Cox proportional hazard regression analyses were performed to identify independent factors associated with OS. Results: The median OS was 13.4 months. In multivariate analysis, molecular-targeted therapy, nephrectomy and surgery for bone metastasis were independent prognostic factors. Bone-modifying agents (BMAs) were not associated with OS. The median OS of patients receiving molecular-targeted therapy after diagnosis of bone metastasis was significantly better than that of those who did not receive targeted therapy. Conclusion: Molecular-targeted therapy, nephrectomy and surgery for bone metastasis should be considered for RCC patients with metastasis in the bones.

引用

页码：5531 / 5536

页数：6

共 25 条

[1] Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases [J].